

Additional file 3:
Supplementary figures S24-S44 -
Observed/expected SAEs before and after
standardization by multimorbidity count

Figure S24: observed/expected SAEs before and after standardization by multimorbidity count: asthma trials




Figure S25: observed/expected SAEs before and after standardization by multimorbidity count: atrial fibrillation trials




Figure S26: observed/expected SAEs before and after standardization by multimorbidity count: axial spondyloarthritis trials




Figure S27: observed/expected SAEs before and after standardization by multimorbidity count: benign prostatic hyperplasia trials




Figure S28: observed/expected SAEs before and after standardization by multimorbidity count: dementia trials




Figure S29: observed/expected SAEs before and after standardization by multimorbidity count: type 2 diabetes mellitus trials




Figure S30: observed/expected SAEs before and after standardization by multimorbidity count: hypertension trials




Figure S31: observed/expected SAEs before and after standardization by multimorbidity count: pulmonary hypertension trials




Figure S32: observed/expected SAEs before and after standardization by multimorbidity count: inflammatory bowel disease trials




Figure S33: observed/expected SAEs before and after standardization by multimorbidity count: migraine trials




Figure S34: observed/expected SAEs before and after standardization by multimorbidity count: osteoarthritis trials




Figure S35: observed/expected SAEs before and after standardization by multimorbidity count: osteoporosis trials




Figure S36: observed/expected SAEs before and after standardization by multimorbidity count: Parkinson's disease trials




Figure S37: observed/expected SAEs before and after standardization by multimorbidity count: psoriasis trials




Figure S3: observed/expected SAEs before and after standardization by multimorbidity count: psoriatic arthropathy trials




Figure S39: observed/expected SAEs before and after standardization by multimorbidity count: chronic obstructive pulmonary disease trials




Figure S40: observed/expected SAEs before and after standardization by multimorbidity count: pulmonary fibrosis trials




Figure S41: observed/expected SAEs before and after standardization by multimorbidity count: restless legs syndrome trials




Figure S42: observed/expected SAEs before and after standardization by multimorbidity count: rheumatoid arthritis trials




Figure S43: observed/expected SAEs before and after standardization by multimorbidity count: systemic lupus erythematosus trials




Figure S44: observed/expected SAEs before and after standardization by multimorbidity count: thromboembolism trials

